<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480348</url>
  </required_header>
  <id_info>
    <org_study_id>Version 5.0, 29 JUL 2019</org_study_id>
    <nct_id>NCT02480348</nct_id>
  </id_info>
  <brief_title>Medtronic RevElution Trial</brief_title>
  <acronym>RevElution</acronym>
  <official_title>Medtronic Polymer-Free Drug-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the clinical safety and efficacy of the Polymer-Free&#xD;
      Drug-Eluting coronary stent system for the treatment of de novo lesions in native coronary&#xD;
      arteries with a reference vessel diameter (RVD) that allows use of stents between 2.25 and&#xD;
      3.50 mm in diameter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2015</start_date>
  <completion_date type="Actual">October 21, 2019</completion_date>
  <primary_completion_date type="Actual">June 16, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss (LLL, in-stent) at 9 months post-procedure as measured by quantitative coronary angiography.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Polymer-free DES (Drug Eluting Stent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polymer-free DES (Drug Eluting Stent)</intervention_name>
    <arm_group_label>Polymer-free DES (Drug Eluting Stent)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be an acceptable candidate for percutaneous coronary intervention, stenting, &amp;&#xD;
             emergent coronary artery bypass graft (CABG) surgery&#xD;
&#xD;
          -  Must have evidence of ischemic heart disease&#xD;
&#xD;
          -  Must require treatment of either a) a single target lesion amenable to treatment with&#xD;
             a 2.25 mm - 3.50 mm stent OR b) two target lesions located in separate target vessels,&#xD;
             with at least one of the target lesions amenable to treatment with a 2.25 mm - 3.50 mm&#xD;
             mm study stent&#xD;
&#xD;
          -  Target lesion(s) must be de novo lesion(s) in native coronary artery(ies)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to aspirin, heparin and bivalirudin,&#xD;
             thienopyridines, cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer&#xD;
             coatings (e.g. BioLinx) or a sensitivity to contrast media, which cannot be adequately&#xD;
             pre-medicated&#xD;
&#xD;
          -  History of an allergic reaction or significant sensitivity to drugs such as&#xD;
             zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative&#xD;
&#xD;
          -  History of a stroke or transient ischemic attack (TIA) within the prior 6 months&#xD;
&#xD;
          -  Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy or will refuse blood transfusions&#xD;
&#xD;
          -  Concurrent medical condition with a life expectancy of less than 5 years&#xD;
&#xD;
          -  Currently participating in an investigational drug or another device trial that has&#xD;
             not completed the primary endpoint&#xD;
&#xD;
          -  Documented left ventricular ejection fraction (LVEF) &lt; 30% at the most recent&#xD;
             evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eastern Heart Clinic - Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Andrew's Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Hospital / HeartCare Partners</name>
      <address>
        <city>Auchenflower</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Center</name>
      <address>
        <city>Bedford Park</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Dante Pazzanese of Cardiology</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Center Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

